Clinical trial

Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

NCT06128148

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-05-04

PhasePHASE1

Study timeline

Study start (actual)2022-05-04Date precision: day

Registry last updated2025-07-14

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Protein Kinase Inhibitorsunresolved

Other Protocol Specified Criteriaunresolved

Lung Neoplasmsunresolved

Brain Neoplasmsunresolved

Interventions

JYP0322 50 mg qdDRUG

JYP0322 100 mg qdDRUG

JYP0322 200 mg qdDRUG

JYP0322 100 mg bidDRUG

JYP0322 150 mg bidDRUG

JYP0322 200 mg bidDRUG

JYP0322 150mg tidDRUG

Sponsors & collaborators

Guangzhou JOYO Pharma Co., Ltdlead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06128148 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.